Last reviewed · How we verify

NCT05989321

A New Approach for Catheter Ablation of Atrial Fibrillation

Completed Last updated 14 August 2023
What this trial tests

trial testing PVI alone in Atrial Fibrillation in 116 participants. Completed in 15 July 2022.

Timeline
1 January 2021
Primary endpoint
30 June 2022
15 July 2022

Quick facts

Lead sponsorThe Second Affiliated Hospital of Kunming Medical University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment116
Start date1 January 2021
Primary completion30 June 2022
Estimated completion15 July 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Second Affiliated Hospital of Kunming Medical University

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a retrospective cohort study of radiofrequency ablation for the treatment atrial fibrillation(AF). Based on the electrophysiological phenomena found in these cases, the investigators propose a hypothesis regarding the underlying electrophysiological mechanism of AF, as well as a novel approach for catheter ablation of AF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PVI alone

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other The Second Affiliated Hospital of Kunming Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing